Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats

Clinical Science

Volumn 122, Issue 10, 2012, Pages 473-483

  Darsalia, Vladimer ^a   Mansouri, Shiva ^a   Orts̈Ater, Henrik ^a   Olverling, Anna ^a   Nozadze, Nino ^a   Kappe, Camilla ^a   Iverfeldt, Kerstin ^b   Tracy, Linda M ^b   Grankvist, Nina ^a   Sjöholm, Åke ^a   Patrone, Cesare ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Exendin 4 (Ex 4); Goto Kakizaki (GK) rat; Middle cerebral artery occlusion (MCAO); Neurogenesis; Neuroprotection

Indexed keywords

ANTIINFLAMMATORY AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN DAMAGE; BRAIN ISCHEMIA; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG EFFICACY; HYPERGLYCEMIA; INFLAMMATION; INSULIN RELEASE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROBLAST; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL; STROKE; TREATMENT DURATION;

ANIMALS; BRAIN ISCHEMIA; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HYPERGLYCEMIA; MALE; MICROGLIA; NEUROGENESIS; NEUROPROTECTIVE AGENTS; PEPTIDES; RATS; RECEPTORS, GLUCAGON; STROKE; STROKE VOLUME; VENOMS;

EID: 84858722980     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110374     Document Type: Article

References (58)

1. Allen, C. L. and Bayraktutan, U. (2008) Risk factors for ischaemic stroke. Int. J. Stroke 3, 105-116
2. Marini, C., Baldassarre, M., Russo, T., De Santis, F., Sacco, S., Ciancarelli, I. and Carolei, A. (2004) Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 62, 77-81
3. Zimmet, P., Alberti, K. G. and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787
4. Sjoholm, A. and Nystrom, T. (2005) Endothelial inflammation in insulin resistance. Lancet 365, 610-612
5. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H. and Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393
6. Sander, D. and Kearney, M. T. (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J. Neurol. 256, 1603-1619
7. Harmsen, P., Lappas, G., Rosengren, A. and Wilhelmsen, L. (2006) Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Goteborg, Sweden. Stroke 37, 1663-1667
8. Kruyt, N. D., Biessels, G. J., Devries, J. H. and Roos, Y. B. (2010) Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat. Rev. Neurol. 6, 145-155
9. Haratz, S. and Tanne, D. (2011) Diabetes, hyperglycemia and the management of cerebrovascular disease. Curr. Opin. Neurol. 24, 81-88
10. Perry, T. and Greig, N. H. (2003) The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol. Sci. 24, 377-383
11. Drucker, D. J. and Nauck, M. A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705
12. Eng, J., Kleinman,W. A., Singh, L., Singh, G. and Raufman, J. P. (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405
13. Goke, R., Larsen, P. J., Mikkelsen, J. D. and Sheikh, S. P. (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7, 2294-2300
14. Hamilton, A. and Holscher, C. (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20, 1161-1166
15. Kastin, A. J. and Akerstrom, V. (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313-318
16. During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J. and Haile, C. N. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173-1179
17. Holst, J. J., Burcelin, R. and Nathanson, E. (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27, 547-558
18. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H. and Wikstrom, L. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326-338
19. Isacson, R., Nielsen, E., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O. and Wikstrom, L. (2011) The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650, 249-255
20. McClean, P. L., Gault, V. A., Harriott, P. and Holscher, C. (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158-162
21. Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S. and Oka, J. (2006) Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci. Res. 55, 352-360
22. Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K. and Hayashi, T. (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53, 2256-2266
23. Kim, S., Moon, M. and Park, S. (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431-439
24. Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K. et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106, 1285-1290
25. Hyun Lee, C., Yan, B., Yoo, K. Y., Choi, J. H., Kwon, S. H., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y. M. and Won, M. H. (2011) Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J. Neurosci. Res. 89, 1103-1113
26. Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N. and Urabe, T. (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 31, 1696-1705
27. Ghanaat-Pour, H. and Sjoholm, A. (2009) Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabetes Metab. Res. Rev. 25, 163-184
28. Tourrel, C., Bailbe, D., Lacorne, M., Meile, M. J., Kergoat, M. and Portha, B. (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51, 1443-1452
29. Koizumi, J., Yoshida, Y., Nakazawa, T. and Ooneda, G. (1986) Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J. Stroke 8, 1-8
30. Reference deleted
31. West, M. J., Slomianka, L. and Gundersen, H. J. (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482-497
32. West, M. J. (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22, 51-61
33. Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z. and Lindvall, O. (2002) Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 8, 963-970
34. Ming, G. L. and Song, H. (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70, 687-702
35. Sena, E., van der Worp, H. B., Howells, D. and Macleod, M. (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 30, 433-439
36. Legos, J. J., Tuma, R. F. and Barone, F. C. (2002) Pharmacological interventions for stroke: failures and future. Expert Opin. Investig. Drugs 11, 603-614
37. Endres, M., Engelhardt, B., Koistinaho, J., Lindvall, O., Meairs, S., Mohr, J. P., Planas, A., Rothwell, N., Schwaninger, M., Schwab, M. E. et al. (2008) Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc. Dis. 25, 268-278
38. Ginsberg, M. D. (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363-389
39. Marini, C., Triggiani, L., Cimini, N., Ciancarelli, I., De Santis, F., Russo, T., Baldassarre, M., di Orio, F. and Carolei, A. (2001) Proportion of older people in the community as a predictor of increasing stroke incidence. Neuroepidemiology 20, 91-95
40. Wahlgren, N. G. and Ahmed, N. (2004) Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc. Dis. 17 (Suppl. 1), 153-166
41. Reference deleted.
42. Saver, J. L. (2006) Time is brain - quantified. Stroke 37, 263-266
43. Henrich-Noack, P., Baldauf, K., Reiser, G. and Reymann, K. G. (2008) Pattern of time-dependent reduction of histologically determined infarct volume after focal ischaemia in mice. Neurosci. Lett. 432, 141-145
44. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J. and Husain, M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340-2350
45. Gromada, J., Ding, W. G., Barg, S., Renstrom, E. and Rorsman, P. (1997) Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch. 434, 515-524
46. Collino, M., Aragno, M., Castiglia, S., Tomasinelli, C., Thiemermann, C., Boccuzzi, G. and Fantozzi, R. (2009) Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3β. Diabetes 58, 235-242
47. LeMay, D. R., Gehua, L., Zelenock, G. B. and D'Alecy, L. G. (1988) Insulin administration protects neurologic function in cerebral ischemia in rats. Stroke 19, 1411-1419
48. Kriz, J. (2006) Inflammation in ischemic brain injury: timing is important. Crit. Rev. Neurobiol. 18, 145-157
49. Wang, X. and Feuerstein, G. Z. (2004) The Janus face of inflammation in ischemic brain injury. Acta Neurochir. Suppl. 89, 49-54
50. Park, H. R., Park, M., Choi, J., Park, K. Y., Chung, H. Y. and Lee, J. (2010) A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci. Lett. 482, 235-239
51. Zhang, W. J., Tan, Y. F., Yue, J. T., Vranic, M. and Wojtowicz, J. M. (2008) Impairment of hippocampal neurogenesis in streptozotocin-treated diabetic rats. Acta Neurol. Scand. 117, 205-210
52. Beauquis, J., Roig, P., Homo-Delarche, F., De Nicola, A. and Saravia, F. (2006) Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment. Eur. J. Neurosci. 23, 1539-1546
53. Suh, S.W., Fan, Y., Hong, S. M., Liu, Z., Matsumori, Y., Weinstein, P. R., Swanson, R. A. and Liu, J. (2005) Hypoglycemia induces transient neurogenesis and subsequent progenitor cell loss in the rat hippocampus. Diabetes 54, 500-509
54. Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M. and Mattson, M. P. (2008) Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11, 309-317
55. Marti-Fabregas, J., Romaguera-Ros, M., Gomez-Pinedo, U., Martinez-Ramirez, S., Jimenez-Xarrie, E., Marin, R., Marti-Vilalta, J. L. and Garcia-Verdugo, J. M. (2010) Proliferation in the human ipsilateral subventricular zone after ischemic stroke. Neurology 74, 357-365
56. Parent, J. M., Vexler, Z. S., Gong, C., Derugin, N. and Ferriero, D. M. (2002) Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann. Neurol. 52, 802-813
57. Nakayama, D., Matsuyama, T., Ishibashi-Ueda, H., Nakagomi, T., Kasahara, Y., Hirose, H., Kikuchi-Taura, A., Stern, D. M., Mori, H. and Taguchi, A. (2010) Injury-induced neural stem/progenitor cells in post-stroke human cerebral cortex. Eur. J. Neurosci. 31, 90-98
58. Thored, P., Arvidsson, A., Cacci, E., Ahlenius, H., Kallur, T., Darsalia, V., Ekdahl, C. T., Kokaia, Z. and Lindvall, O. (2006) Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 24, 739-747